Stocks Health care TTRX
NASDAQ · Health careTurn Therapeutics Inc. (TTRX)
It posted a net loss of $12.8M. At September 30, 2026 it held $9.4M in cash against $7.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Turn Therapeutics Inc.
- Net worth
- Turn Therapeutics Inc. has a market value (market cap) of $291.6M at the latest share price, and shareholders' equity of $5.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $2.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Turn Therapeutics Inc.'s next report is expected around March 30, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Turn Therapeutics Inc. does
Turn Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TTRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$3.2M | -$0.12 | n/a |
| 2025 | n/a | -$1.8M | -$0.07 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Turn Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 9, 2026
- November 9, 2026
- October 19, 2026
- October 19, 2026Proxy statement DEF 14A
- October 7, 2026
- September 10, 2026
- September 9, 2026
- August 18, 2026
Insider trades
What the people running Turn Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 28, 2026 | Burnam Bradley EvanChief Executive Officer, Director, 10% owner | Gave as a giftindirect | 300,000 | - |
| May 28, 2026 | Burnam Bradley EvanChief Executive Officer, Director, 10% owner | Gave as a giftindirect | 300,000 | - |
| May 28, 2026 | Burnam Bradley EvanChief Executive Officer, Director, 10% owner | Gave as a giftindirect | 300,000 | - |
| May 28, 2026 | Burnam Bradley EvanChief Executive Officer, Director, 10% owner | Gave as a giftindirect | 300,000 | - |
| April 2, 2026 | Golden Arthur FDirector | Gave as a gift | 300,000 | - |
| April 2, 2026 | Burnam Bradley EvanChief Executive Officer, Director, 10% owner | Gave as a giftindirect | 300,000 | - |
| January 7, 2026 | Dewhurst Martin WilliamDirector | Received as pay | 21,882 | - |
| December 12, 2025 | Chaudhary ZuraizSee Remarks | Bought | 2,500 | $8.8K |
Who owns TTRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bradley Burnam13G, passive | 52.76% | April 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 29 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| SteelPeak Wealth, LLC | 249,456 | new |
| Ieq Capital, LLC | 227,396 | new |
| DDFG, Inc | 107,829 | +37,295 |
| Vanguard Capital Management LLC | 74,301 | +24,851 |
| Wellington Shields & Co., LLC | 65,732 | 0 |
| Millennium Management LLC | 60,551 | -9,206 |
| BlackRock, Inc. | 38,591 | new |
| Bridgewater Advisors Inc. | 27,326 | new |
| Aaron Wealth Advisors LLC | 32,564 | new |
| Tamar Securities, LLC | 30,000 | 0 |
| Royal Bank of Canada | 28,250 | new |
| Citadel Advisors LLC | 25,874 | new |
| Brown Brothers Harriman & Co | 23,688 | 0 |
| HighTower Advisors, LLC | 19,684 | 0 |
| RVW Wealth, LLC | 18,000 | 0 |
| Geode Capital Management, LLC | 17,142 | 0 |
| Jefferies Financial Group Inc. | 16,300 | new |
| Composition Wealth, LLC | 16,000 | 0 |
| McCarthy Asset Management, Inc. | 15,018 | new |
| Bank of America Corp | 14,124 | 0 |
Insiders
4 insiders reported holding 694,984 shares in total, about $6.8M at the last price.
| Holder | Shares |
|---|---|
| Golden Arthur FDirector | 360,602 |
| Burnam Bradley EvanChief Executive Officer, Director, 10% owner | 300,000300,000 held indirectly |
| Dewhurst Martin WilliamDirector | 21,882 |
| Chaudhary ZuraizSee Remarks | 12,500 |
Questions about TTRX
What does Turn Therapeutics Inc. do?
Turn Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as TTRX. Its shares trade on NASDAQ under the ticker TTRX.
What is Turn Therapeutics Inc.'s net worth?
Turn Therapeutics Inc. has a market value (market cap) of $291.6M at the latest share price, and shareholders' equity of $5.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Turn Therapeutics Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $12.8M.
When did Turn Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Turn Therapeutics Inc.'s next earnings report?
Turn Therapeutics Inc.'s next report is expected around March 30, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TTRX with
Follow TTRX
Get an email when Turn Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Turn Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.